Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Acalabrutinib in Relapsed CLL/SLL
NCT04523428Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Dec 2020
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of venetoclax, acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by HOVON. Started Dec 2020; status: recruiting.
02
Drugs
venetoclaxacalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04523428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523428.